🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to health experts.

A Global Challenge

The sexually transmitted infection are escalating around the world, with data suggesting more than 82 million infections per year. Particularly high rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, the spread of superbugs and the very limited treatment choices currently available.”

Public health authorities are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has designated it as a "high-priority threat". Recent surveillance revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Clearance

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in the same week. This drug, which is employed against UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Development Model

This new treatment stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a significant shift in the management of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Data and Global Access

Based on data detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which involves a dual-drug approach. The research included hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. The availability of a one-pill regimen such as this is hailed as a "game-changer" for managing the epidemic. This is viewed as vital to reduce the burden of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.